New Products Posted to GenomeWeb: Roche, Genomenon, Precipio, More

Roche Navify Clinical Trial Match, Navify Publication Search

Roche has launched two Navify clinical decision support apps, Navify Clinical Trial Match and Navify Publication Search, to help oncologists access clinical trial information and publications. Both are available on the Navify Tumor Board platform.

The Navify Clinical Trial Match app identifies clinical trial options from 11 international registries, based on patient-specific attributes such as age, sex, biomarkers, and various tumor attributes. The registries include ClinicalTrials.gov, the German Clinical Trials Registry, and the European Clinical Trials Registry. The Navify Publication Search app mines several publication sources, including PubMed, the American Society of Clinical Oncology, and the American Association of Central Cancer Registries, for relevant literature. The content of both apps is provided by MolecularMatch, a clinical informatics company.

Roche said it plans to add more apps, including from partners and third parties, in the future.

Genomenon Mastermind Genomic Search Engine

The latest release of Genomenon's Mastermind Genomic Search Engine indexes approximately 5 million new genomic variants from supplemental data found in scientific publications. Most precision medicine tools have not been able to provide insight into supplemental data without manual curation due to the lack of a common file format, the company noted. Supplemental data is often published as an Excel, PDF, .csv, Word, text, or image file. Genomenon said that it overcame this challenge by engineering its indexing pipeline to ingest these different file formats and applying its proprietary Genomic Language Processing technology to index the content for easy retrieval by researchers.  

Precipio EGFR Liquid Biopsy Kit

Precipio has launched a new liquid biopsy ICEme kit, which uses the company's ICE-COLD PCR technology to enrich and detect cancer mutations in EGFR exons 18, 19, 20, and 21. The kit uses either qPCR or Sanger platforms with sensitivity down to 0.1 percent allele frequency. The new product complements Precipio's previously-launched TKI-resistance detection kit, which includes assays for EGFR exon 20 T790M and C797S resistance mutations.

For more new products and services, please visit the New Products page on our website.